Q2 2024 EPS Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Cut by William Blair

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at William Blair dropped their Q2 2024 earnings per share (EPS) estimates for Neurocrine Biosciences in a research note issued to investors on Wednesday, May 1st. William Blair analyst M. Minter now forecasts that the company will post earnings per share of $1.11 for the quarter, down from their prior estimate of $1.14. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.78 per share. William Blair also issued estimates for Neurocrine Biosciences’ Q3 2024 earnings at $1.23 EPS, Q4 2024 earnings at $1.25 EPS, FY2024 earnings at $4.46 EPS, Q1 2025 earnings at $1.33 EPS, Q2 2025 earnings at $1.61 EPS, Q3 2025 earnings at $1.80 EPS, Q4 2025 earnings at $2.03 EPS and FY2025 earnings at $6.77 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.31. The firm had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. The firm’s quarterly revenue was up 25.0% on a year-over-year basis. During the same period last year, the firm posted $0.88 EPS.

A number of other equities research analysts have also recently weighed in on NBIX. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, May 1st. Guggenheim lifted their price target on Neurocrine Biosciences from $164.00 to $170.00 and gave the company a “buy” rating in a report on Thursday. Wells Fargo & Company upgraded shares of Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $140.00 to $170.00 in a research report on Wednesday, April 24th. Mizuho raised their price objective on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research report on Thursday, February 8th. Finally, Oppenheimer boosted their target price on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday. Six research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $147.88.

Neurocrine Biosciences Trading Up 0.6 %

NASDAQ:NBIX opened at $140.71 on Monday. The stock has a market capitalization of $14.16 billion, a P/E ratio of 38.76 and a beta of 0.28. Neurocrine Biosciences has a 1 year low of $89.04 and a 1 year high of $148.37. The firm has a 50 day moving average of $137.37 and a 200-day moving average of $129.00.

Institutional Trading of Neurocrine Biosciences

Hedge funds have recently added to or reduced their stakes in the business. Mather Group LLC. acquired a new stake in Neurocrine Biosciences during the 1st quarter worth $26,000. Headinvest LLC acquired a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at about $28,000. Lindbrook Capital LLC raised its stake in shares of Neurocrine Biosciences by 85.0% in the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after purchasing an additional 96 shares during the period. EdgeRock Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at about $31,000. Finally, Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at about $33,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity

In other news, insider Eric Benevich sold 19,818 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the transaction, the insider now owns 40,778 shares of the company’s stock, valued at approximately $5,438,154.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the sale, the insider now owns 40,778 shares of the company’s stock, valued at approximately $5,438,154.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director George J. Morrow sold 40,000 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $139.42, for a total value of $5,576,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 181,547 shares of company stock valued at $25,039,887 in the last 90 days. 4.30% of the stock is owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.